Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?

Journal of Diabetes Investigation

Volumn 5, Issue 5, 2014, Pages 475-477

  Yabe, Daisuke ^a,b,c   Seino, Yutaka ^a  

^a Center for Diabetes Endocrinology and Metabolism   (Japan)

^b KANSAI ELECTRIC POWER CO   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLIMEPIRIDE; INCRETIN; LIRAGLUTIDE; REACTIVE OXYGEN METABOLITE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

BINDING AFFINITY; CONFORMATIONAL TRANSITION; DISEASE SEVERITY; DRUG BINDING; DRUG SAFETY; EDITORIAL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; HYPOGLYCEMIC COMA; KIDNEY FAILURE; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMARKETING SURVEILLANCE; RISK ASSESSMENT; SIGNAL TRANSDUCTION;

EID: 84908569527     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12229     Document Type: Editorial

References (5)

1. Seino Y, Yabe D. GIP and GLP-1: incretin actions beyond pancreas. J Diabetes Invest 2013; 4: 108-130.
2. Mukai E, Fujimoto S, Sato H, et al. Exendin-4 suppresses SRC activation and reactive oxygen species production in diabetic Goto-Kakizaki rat islets in an Epac-dependent manner. Diabetes 2010; 60: 218-226.
3. Mukai E, Ishida H, Kato S, et al. Metabolic inhibition impairs ATP-sensitive K+ channel block by sulfonylurea in pancreatic beta-cells. Am J Physiol 1998; 274: E38-E44.
4. Zhang CL, Katoh M, Shibasaki T, et al. The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science 2009; 325: 607-610.
5. Takahashi T, Shibasaki T, Takahashi H, et al. Antidiabetic Sulfonylureas and cAMP Cooperatively Activate Epac2A. Sci Signal 2013; 6: ra94.